Format:
1 Online-Ressource (291 Seiten)
ISBN:
9783527819850
Note:
Description based on publisher supplied metadata and other sources
,
Cover -- Title Page -- Copyright -- Contents -- Foreword -- Preface -- Chapter 1 We Need An Entrepreneurial Culture in Chemistry: Do You Have What It Takes to be a Chemistry Entrepreneur? -- 1.1 Introduction: Disruptive Innovation in Chemistry is in High Demand -- 1.2 Examples of Innovation in Chemistry Catching the Eye of the Mainstream Market -- 1.2.1 Food and Nutrition -- 1.2.1.1 Just (formerly Hampton Creek) -- 1.2.1.2 Impossible Foods -- 1.2.1.3 Perfect Day -- 1.2.1.4 Endless West (formerly Ava Winery) -- 1.2.2 Sustainable/Renewable Chemistry -- 1.2.2.1 Ginkgo Bioworks -- 1.2.2.2 Modern Meadow -- 1.2.2.3 Genomatica -- 1.2.2.4 Zymergen -- 1.2.3 Biotech/Pharma -- 1.2.3.1 Moderna Therapeutics -- 1.2.3.2 Unity Biotechnology -- 1.2.3.3 CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine -- 1.2.4 Diagnostics -- 1.2.4.1 23andme -- 1.2.4.2 Grail Diagnostics -- 1.2.4.3 Viome -- 1.2.5 Cautionary Tales -- 1.2.5.1 Theranos -- 1.2.5.2 Solazyme (TerraVia) -- 1.3 Unique Challenges for Chemistry Entrepreneurs -- 1.3.1 The Most Important Trait of Every Chemical Entrepreneur -- 1.3.2 Chemistry Accelerators, Incubators, and Academic Spin‐offs -- 1.3.3 Do Something, do Anything, even if it is Wrong -- 1.3.3.1 Penicillin -- 1.3.3.2 Post‐It -- 1.3.3.3 Saccharin -- 1.3.3.4 Teflon -- 1.3.3.5 Viagra -- 1.3.4 You have your Discovery -- now you need a Patent -- 1.3.4.1 Provisional Patent -- 1.3.4.2 Patent Application -- 1.3.4.3 Patent Prosecution -- 1.3.4.4 Structure of the Patent Claims -- 1.3.4.5 Patent Search and Prior Art -- 1.3.4.6 Publishing Before Patenting -- 1.3.4.7 PCT International Patent -- 1.3.4.8 Protectable Patent Value -- 1.3.4.9 Selecting the Wrong Lawyer for the Job -- 1.4 Invention is Only the Beginning of Creating a Company -- 1.4.1 Know your Role: Founding CEO vs. Founder vs. Inventor
,
1.4.2 Raising Money: Acquiring the Right Money at the Right Time -- 1.4.2.1 Self‐funding -- 1.4.2.2 Friends and Family -- 1.4.2.3 Angel Investors -- 1.4.2.4 Accelerators and Incubators -- 1.4.2.5 Debt -- 1.4.2.6 Strategic Investment -- 1.4.2.7 Private Equity -- 1.4.2.8 Venture Capital -- 1.4.2.9 Investment Banks -- 1.4.3 Can you get the idea for Commercialization? -- 1.4.4 When you are Ready to Commercialize, which path do you take? -- 1.4.4.1 Licensing Deal -- 1.4.4.2 Business‐to‐Business (B2B) -- 1.4.4.3 Business‐to‐Consumer (B2C) -- 1.5 Do you have the Traits of an Entrepreneur? -- 1.6 Summary: Do You Have What It Takes? -- Recommended Readings and References -- Author Biography -- Chapter 2 Taking Ideas Out of the Lab: Why and When to Start a Company in the Biomedical Field -- 2.1 Introduction -- 2.2 Company Case Studies: Interviews with the Founding Scientists -- 2.2.1 Advanced Inhalation Research: Interview with David Edwards -- 2.2.1.1 Core Technology -- 2.2.1.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.1.3 Why was it Important to Start Advanced Inhalation Research? -- 2.2.1.4 When was the Technology Ready to Start Advanced Inhalation Research? -- 2.2.1.5 What Lessons Did You Learn Through This Process? -- 2.2.1.6 Current Status -- 2.2.2 Kala Pharmaceuticals: Interview with Justin Hanes -- 2.2.2.1 Core Technology -- 2.2.2.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.2.3 Why was it Important to Start Kala Pharmaceuticals? -- 2.2.2.4 When was the Technology Ready to Start Kala Pharmaceuticals? -- 2.2.2.5 What Lessons Did You Learn Through This Process? -- 2.2.2.6 Current Status -- 2.2.3 Moderna: Interview with Derrick Rossi -- 2.2.3.1 Core Technology -- 2.2.3.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.3.3 Why was it Important to Start Moderna?
,
2.2.3.4 When was the Technology Ready to Start Moderna? -- 2.2.3.5 What Lessons Did You Learn Through This Process? -- 2.2.3.6 Current Status -- 2.2.4 Sigilon Therapeutics: Interview with Arturo Vegas -- 2.2.4.1 Core Technology -- 2.2.4.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.4.3 Why was it Important to Start Sigilon? -- 2.2.4.4 When was the Technology Ready to Start Sigilon? -- 2.2.4.5 What Lessons Did You Learn Through This Process? -- 2.2.4.6 Current Status -- 2.2.5 Suono Bio: Interview with Carl Schoellhammer -- 2.2.5.1 Core Technology -- 2.2.5.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.5.3 Why was it Important to Start Suono Bio? -- 2.2.5.4 When was the Technology Ready to Start Suono Bio? -- 2.2.5.5 What Lessons Did You Learn Through This Process? -- 2.2.5.6 Current Status -- 2.2.6 Vivtex: Interview with Thomas von Erlach -- 2.2.6.1 Core Technology -- 2.2.6.2 What was the Key Problem and Initial Idea that Sparked the Work? -- 2.2.6.3 Why was it Important to Start Vivtex? -- 2.2.6.4 When was the Technology Ready to Vivtex? -- 2.2.6.5 What Lessons Did You Learn Through This Process? -- 2.2.6.6 Current Status -- 2.3 Why Start a Company? -- 2.3.1 To Have the Largest Impact on Patients -- 2.3.2 To Introduce a New Platform Technology -- 2.3.3 Is Licensing an Alternative? -- 2.3.3.1 Licensing to Existing Companies -- 2.3.3.2 Corporate‐sponsored Academic Research -- 2.4 When to Start a Company? -- 2.4.1 Is There Enough In Vivo Validation? -- 2.4.2 Was a Patent Filed? -- 2.4.3 Was a Paper Published? -- 2.5 The Secret Ingredient: Who and What? -- 2.5.1 Who Will Start the Company? -- 2.5.1.1 Seasoned Mentors as Co‐founders -- 2.5.1.2 Finding a Great CEO -- 2.5.2 What Will the Company Actually Sell? -- 2.6 Summary: Lessons Learned -- 2.6.1 Lesson 1: Work on a High‐impact, Platform Technology
,
2.6.2 Lesson 2: Patent Early and Broadly -- 2.6.3 Lesson 3: Keep the Tech in the Lab as Long as Possible -- 2.6.4 Lesson 4: Must have in vivo Efficacy and Safety -- 2.6.5 Lesson 5: Publish in Top Scientific Journals -- 2.6.6 Lesson 6: Partner with Seasoned Entrepreneurs -- Further Reading -- Author Biographies -- Chapter 3 In Pursuit of New Product Opportunities: Transferring Technology from Lab to Market -- 3.1 Introduction -- 3.1.1 Entrepreneurship and Technology Transfer -- 3.1.2 Pursuing Commercial Product/Service Opportunities via Technology Transfer -- 3.1.3 A Model for Entrepreneurship via Technology Transfer -- 3.1.4 Extracting Technologies from Research Institutions -- 3.2 Technology Discovery and Development -- 3.2.1 Origins of Technology -- 3.2.2 Technology Transfer Communication Models -- 3.2.3 Transitioning Technologies into Products -- 3.2.4 Timing Technology with Industry Acceptance -- 3.3 Customer Discovery and Development -- 3.3.1 Origins of Market Demand and Unmet Needs -- 3.3.2 Identifying a Technology's Uses -- 3.3.3 The Value Chain for Target Applications -- 3.3.4 Identifying Stakeholders in the Value Chain -- 3.3.5 Designing Product Experiments -- 3.3.6 Customer Discovery and Validation Model -- 3.3.6.1 Customer Routines Analysis -- 3.4 Case Study: The Naval Research Laboratory's Self‐Decontaminating Material -- 3.4.1 The Challenge -- 3.4.2 The Scientist -- 3.4.3 The Problem -- 3.4.4 The Solution -- 3.4.5 The Future of the Technology and Future Applications -- 3.4.6 Technology Background and Advantages -- 3.4.7 Benefits -- 3.4.8 Problem -- 3.4.9 Technical Approach -- 3.4.10 Solution -- 3.4.11 Industrial Safety and Hygiene -- 3.4.12 Healthcare and Pharmaceuticals -- 3.4.13 First Response -- Suggested Reading and Resources -- Author Biography -- Chapter 4 Financing and Business Development for Hard Tech Startups
,
4.1 Introduction -- 4.2 Challenges in Financing Hard Tech Startups -- 4.2.1 Balancing Ambition with Reality -- 4.2.2 Hard Tech Sure Is Not Software -- 4.2.3 Hard Tech Investors Are a Skeptical Bunch -- 4.2.4 What Do You Mean I Will Not Exit for 1B? -- 4.2.5 Hard Tech Fundraising Dissonance -- 4.3 Fundraising the Right Way -- 4.3.1 What Kind of Investors Should You Raise from? -- 4.3.1.1 Friends and Family -- 4.3.1.2 Angels -- 4.3.1.3 Early‐Stage Institutional Venture Capitalists -- 4.3.1.4 Late‐Stage Institutional Venture Capitalists -- 4.3.1.5 Corporate Venture Capital -- 4.3.2 Venture Capital Uncovered -- 4.3.2.1 Fund Life -- 4.3.2.2 Return the Fund -- 4.3.2.3 The Mythical 10× and Why It Is Important to You -- 4.3.3 How to Generate Interest from Investors? -- 4.3.3.1 Team -- 4.3.3.2 Differentiated Technology and Customer Value Proposition -- 4.3.3.3 Large Target Market -- 4.3.3.4 Compelling Plan to Build a Business -- 4.4 The Case for Early‐Stage Business Development -- 4.4.1.1 Playbook for Early‐Stage Business Development -- 4.4.1.2 Getting Started -- 4.4.1.3 Getting to the Finish Line -- 4.4.1.4 Avoiding Common Pitfalls -- 4.5 Summary -- Suggested Reading -- Author Biographies -- Chapter 5 Battery Entrepreneurship: Gameboard from Lab to Market -- 5.1 Introduction -- 5.2 Finding a Market Fit for Your Technology -- 5.3 Energy Storage Markets -- 5.3.1 Portable Electronics, Drones, and Medical Devices -- 5.3.2 Grid Energy Storage and Renewable Energy -- 5.3.3 Industrial Batteries and Back‐up Power -- 5.3.4 Home Energy Storage -- 5.3.5 Electric Vehicles -- 5.3.5.1 Passenger Cars -- 5.3.5.2 Light Electric Utility Vehicles -- 5.3.5.3 Heavy‐duty Utility Vehicles, Trucks, and Buses -- 5.3.6 Other Nascent Energy Storage Markets -- 5.3.7 Airplanes -- 5.3.8 Ships and Boats -- 5.4 Battery Startup Case Studies -- 5.4.1 Boston Power -- 5.4.2 A123 Systems
,
5.4.3 Aquion Energy
Additional Edition:
Erscheint auch als Druck-Ausgabe García-Martínez, Javier Chemistry Entrepreneurship Newark : John Wiley & Sons, Incorporated,c2021 ISBN 9783527345441
Language:
English
Subjects:
Engineering
,
Chemistry/Pharmacy
Keywords:
Chemische Industrie
;
Entrepreneurship
Bookmarklink
